FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2051244114> ?p ?o ?g. }

• W2051244114 endingPage "190" @default.
• W2051244114 startingPage "185" @default.
• W2051244114 abstract "Background Alcohol and tobacco dependence are highly comorbid disorders, with preclinical evidence suggesting a role for nicotinic acetylcholine receptors (nAChRs) in alcohol consumption. Varenicline, a partial nicotinic agonist with high affinity for the α4β2 nAChR receptor, reduced ethanol intake in rodents. We aimed to test whether varenicline would reduce alcohol consumption and alcohol craving in humans. Methods This double-blind, placebo-controlled investigation examined the effect of varenicline (2 mg/day vs. placebo) on alcohol self-administration using an established laboratory paradigm in non-alcohol-dependent heavy drinkers (n = 20) who were daily smokers. Following 7 days of medication pretreatment, participants were first administered a priming dose of alcohol (.3 g/kg) and subjective, and physiologic responses were assessed. A 2-hour alcohol self-administration period followed during which participants could choose to consume up to 8 additional drinks (each .15 g/kg). Results Varenicline (.5 ± SE = .40) significantly reduced the number of drinks consumed compared to placebo (2.60 ± SE = .93) and increased the likelihood of abstaining from any drinking during the self-administration period. Following the priming drink, varenicline attenuated alcohol craving and reduced subjective reinforcing alcohol effects (high, like, rush, feel good, intoxicated). Adverse events associated with varenicline were minimal and, when combined with alcohol, produced no significant effects on physiologic reactivity, mood, or nausea. Conclusions This preliminary investigation demonstrated that varenicline significantly reduced alcohol self-administration and was well tolerated, alone and in combination with alcohol in heavy-drinking smokers. Varenicline should be investigated as a potential treatment for alcohol use disorders. Alcohol and tobacco dependence are highly comorbid disorders, with preclinical evidence suggesting a role for nicotinic acetylcholine receptors (nAChRs) in alcohol consumption. Varenicline, a partial nicotinic agonist with high affinity for the α4β2 nAChR receptor, reduced ethanol intake in rodents. We aimed to test whether varenicline would reduce alcohol consumption and alcohol craving in humans. This double-blind, placebo-controlled investigation examined the effect of varenicline (2 mg/day vs. placebo) on alcohol self-administration using an established laboratory paradigm in non-alcohol-dependent heavy drinkers (n = 20) who were daily smokers. Following 7 days of medication pretreatment, participants were first administered a priming dose of alcohol (.3 g/kg) and subjective, and physiologic responses were assessed. A 2-hour alcohol self-administration period followed during which participants could choose to consume up to 8 additional drinks (each .15 g/kg). Varenicline (.5 ± SE = .40) significantly reduced the number of drinks consumed compared to placebo (2.60 ± SE = .93) and increased the likelihood of abstaining from any drinking during the self-administration period. Following the priming drink, varenicline attenuated alcohol craving and reduced subjective reinforcing alcohol effects (high, like, rush, feel good, intoxicated). Adverse events associated with varenicline were minimal and, when combined with alcohol, produced no significant effects on physiologic reactivity, mood, or nausea. This preliminary investigation demonstrated that varenicline significantly reduced alcohol self-administration and was well tolerated, alone and in combination with alcohol in heavy-drinking smokers. Varenicline should be investigated as a potential treatment for alcohol use disorders." @default.
• W2051244114 created "2016-06-24" @default.
• W2051244114 creator A5007341912 @default.
• W2051244114 creator A5017106491 @default.
• W2051244114 creator A5020907559 @default.
• W2051244114 creator A5024294659 @default.
• W2051244114 creator A5038076892 @default.
• W2051244114 creator A5048526055 @default.
• W2051244114 creator A5062404491 @default.
• W2051244114 creator A5067293178 @default.
• W2051244114 creator A5070108203 @default.
• W2051244114 creator A5079971542 @default.
• W2051244114 date "2009-07-01" @default.
• W2051244114 modified "2023-10-16" @default.
• W2051244114 title "Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers" @default.
• W2051244114 cites W1500971499 @default.
• W2051244114 cites W1571140265 @default.
• W2051244114 cites W1965725321 @default.
• W2051244114 cites W1970168883 @default.
• W2051244114 cites W1973286730 @default.
• W2051244114 cites W1980005460 @default.
• W2051244114 cites W1980637329 @default.
• W2051244114 cites W1981963493 @default.
• W2051244114 cites W1983676227 @default.
• W2051244114 cites W1988791157 @default.
• W2051244114 cites W1993112595 @default.
• W2051244114 cites W2005267747 @default.
• W2051244114 cites W2007188824 @default.
• W2051244114 cites W2011791532 @default.
• W2051244114 cites W2014386887 @default.
• W2051244114 cites W2016691339 @default.
• W2051244114 cites W2021147608 @default.
• W2051244114 cites W2033414461 @default.
• W2051244114 cites W2043442821 @default.
• W2051244114 cites W2050894849 @default.
• W2051244114 cites W2058218561 @default.
• W2051244114 cites W2064449076 @default.
• W2051244114 cites W2071626900 @default.
• W2051244114 cites W2079726518 @default.
• W2051244114 cites W2092120977 @default.
• W2051244114 cites W2094989224 @default.
• W2051244114 cites W2099342322 @default.
• W2051244114 cites W2100760639 @default.
• W2051244114 cites W2101372918 @default.
• W2051244114 cites W2107200746 @default.
• W2051244114 cites W2110569081 @default.
• W2051244114 cites W2126739627 @default.
• W2051244114 cites W2147927117 @default.
• W2051244114 cites W2149628368 @default.
• W2051244114 cites W2152418590 @default.
• W2051244114 cites W2155519999 @default.
• W2051244114 cites W2162128654 @default.
• W2051244114 cites W2164386461 @default.
• W2051244114 cites W2170081966 @default.
• W2051244114 cites W2171354554 @default.
• W2051244114 cites W2315228347 @default.
• W2051244114 cites W4231795951 @default.
• W2051244114 doi "https://doi.org/10.1016/j.biopsych.2009.01.029" @default.
• W2051244114 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2863311" @default.
• W2051244114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19249750" @default.
• W2051244114 hasPublicationYear "2009" @default.
• W2051244114 type Work @default.
• W2051244114 sameAs 2051244114 @default.
• W2051244114 citedByCount "273" @default.
• W2051244114 countsByYear W20512441142012 @default.
• W2051244114 countsByYear W20512441142013 @default.
• W2051244114 countsByYear W20512441142014 @default.
• W2051244114 countsByYear W20512441142015 @default.
• W2051244114 countsByYear W20512441142016 @default.
• W2051244114 countsByYear W20512441142017 @default.
• W2051244114 countsByYear W20512441142018 @default.
• W2051244114 countsByYear W20512441142019 @default.
• W2051244114 countsByYear W20512441142020 @default.
• W2051244114 countsByYear W20512441142021 @default.
• W2051244114 countsByYear W20512441142022 @default.
• W2051244114 countsByYear W20512441142023 @default.
• W2051244114 crossrefType "journal-article" @default.
• W2051244114 hasAuthorship W2051244114A5007341912 @default.
• W2051244114 hasAuthorship W2051244114A5017106491 @default.
• W2051244114 hasAuthorship W2051244114A5020907559 @default.
• W2051244114 hasAuthorship W2051244114A5024294659 @default.
• W2051244114 hasAuthorship W2051244114A5038076892 @default.
• W2051244114 hasAuthorship W2051244114A5048526055 @default.
• W2051244114 hasAuthorship W2051244114A5062404491 @default.
• W2051244114 hasAuthorship W2051244114A5067293178 @default.
• W2051244114 hasAuthorship W2051244114A5070108203 @default.
• W2051244114 hasAuthorship W2051244114A5079971542 @default.
• W2051244114 hasBestOaLocation W20512441142 @default.
• W2051244114 hasConcept C118552586 @default.
• W2051244114 hasConcept C126322002 @default.
• W2051244114 hasConcept C142724271 @default.
• W2051244114 hasConcept C15744967 @default.
• W2051244114 hasConcept C170493617 @default.
• W2051244114 hasConcept C178790620 @default.
• W2051244114 hasConcept C185592680 @default.
• W2051244114 hasConcept C188987157 @default.
• W2051244114 hasConcept C204787440 @default.
• W2051244114 hasConcept C27081682 @default.

• next